TRIM21 and acquired idiopathic inflammatory myopathy: Current clinical evidence suggests that the presence of anti-TRIM21 antibodies is associated with an increased incidence of concomitant ILD in SjS, SSc, and IIM, with a higher probability of ILD occurring and being more severe, usually predicting poorer outcomes and survival.